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If not, how do you presently select the right stent for an individual
patient.
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Dr Charles B. Ross (Louisville, KY). I would like to congrat-
ulate Dr Timaran and his colleagues from the University of Texas,
Southwestern for an excellent paper which represents another mile-
stone in their efforts to differentiate patient, device, and technical
factors which might have utility in helping us to more safely imple-
ment carotid artery stenting. The question posed in the present study
relates to open vs closed-cell stent design and whether this influences
intra-procedural cerebral embolization as a surrogate for adverse
neurological outcomes. And, you showed no differences in either
intra-procedural TCD microembolic signals or early DW-MRI
changes between the two stent designs.
Yet, one-third ormore adverse neurologic events occur 24 hours
to 30 days following completion of CAS. In the present study, you
report the occurrence of a stroke 3 days postprocedure in an asymp-
tomatic patient in the open cell group and one transient ischemic
attack in a an open-cell patient at 19 days postprocedure. My first
observation is that your study designwith use of intra-proceduralTCD
and early 18 to 24 hour postprocedural MRI as surrogates for adverse
neurologic outcomemay not precisely address the clinical question as to
the ultimate potential superiority of one stent design over the other.
Can you review for us the specific information as to the plaque
morphology in the two patients who had adverse neurologic events as
well as any additional insight as to what happened in those cases? Are
you completely comfortable that intra-procedural embolization as a
surrogates for adverse neurologic events adequately addresses the clinical
question as to the ultimate benefit of closed cell versus open cell stents?
When I look at the issue of closed-cell vs open-cell stents forCAS,
I must reflect on the Belgium- Italian Carotid (BIC) Registry1 in
which this issue of superiority of closed-cell stents was initially raised.
In that registry, the difference between designs was primarily seen in
symptomatic patients and much emphasis was made on the particu-
larly protective benefit of closed-cell stents in terms of reduction
postprocedure events. In the study reported by Schillinger, at al,2
there was a nonsignificant trend towards fewer “subacute” events in
patients who hadCASwith closed-cell stents. The studymay not have
been adequately powered to demonstrate an effect. The MRIs were
performed early in your study. Did you consider delaying theMRI to
better reflect postprocedure events?
In the BIC registry, the vast majority of closed-cell stents were
carotid Wallstents. Why did you use only the EXACT stent? Did you
consider use of the carotid Wallstent? Do you think it would have
made a difference?
Third, we continue to seek refinements in carotid artery tech-
nique based on preprocedural patient, anatomic, and plaque char-
acteristics. However, your findings last year on plaque morphol-
ogy3 and now this year on stent design have not confirmed
conventional wisdom from observational studies and have failed to
provide positive technical guidance.
So, I ask you now, do you use the same system for every patient?I greatly appreciate receipt this manuscript with plenty of time
o review, and I thank the society for the privilege of the floor to
pen this discussion.
DrCarlosH. Timaran.Thank you,Charles, for your questions
nd comments. First, yes, there were two events: one TIA that
appened almost 19 days after the procedure and then aminor stroke
hat happened 3 days after the procedure. Of note, none of those
atients actually have a positive MRI for cerebral embolization, but
ne could argue that a lateMRIwould have revealedmicroemboli. As
ar as the plaque composition of those two patients, it was not
articularly relevant. Both had about 10% proportion of necrotic core
ut there were no other relevant plaque composition features.
You asked me what I think about using TCD and MRI as
urrogates for adverse neurologic events. I have to say that after the
REST trial, we have two procedures, stenting and endarterectomy,
hich are really good and have a really low number of positive
utcome events in terms of strokes and deaths. To avoid designing
arge and expensive trials, it has been suggested that surrogate end
oints should be used, and in fact, the ICSS substudy used cerebral
mbolization detectedwithDW-MRI as a surrogate end point, which
roved to be actually a very good one and helped to solve some bias
ssues applicable to the whole cohort of patients.
Why did we choose Xact stents? It was primarily because it was
he only one available. As you know the carotid Wallstent was ap-
roved later. When we designed this study and submitted our grant
roposal the only closed-cell stent we had available was the Xact stent.
ow, yes, I agree that this study in a way contradicts what is being
hown by other observational studies, but the importance of doing
andomized clinical trials is that you compare directly two different
reatment groups without the bias of patient or case selection.
Howdo I choose a stent?Well, I have to say that at this pointwith
he stents we have, I don’t think stent design is that important. I focus
ore on the type of embolic protection based on symptomatic status.
also focusmore on anatomy. I always try to get CTAs, particularly in
ctogenarians that I am considering for stenting. I think in the future
s absorbable stents or those stents constructed with high-density
eshes or cover stents become available, wewill actually use stent design
s a way to improve the results of carotid stenting.
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